BridgeBio Oncology Therapeutics Inc.

BBOT | NASDAQ

$4.66

-$0.11 (-2.31%)

At close: Sep 21, 2026, 4:00 PM ET

$4.55

-$0.11 (-2.36%)

Pre-market: Sep 22, 2026, 8:24 AM ET

Fiscal Year Period Ending	FY 2025 Dec 30, 2025	FY 2024 Dec 30, 2024	FY 2023 Dec 30, 2023	FY 2022 Dec 30, 2022	FY 2021 Dec 30, 2021
PE Ratio	-2.91	22.83	-3.22	-59.3K	-4.85K
PEG Ratio	0	-0.20	n/a	593.02	n/a
PS Ratio	n/a	n/a	n/a	n/a	n/a
PB Ratio	0.95	0.93	-3.28K	-9.54K	-11.37K
P/FCF Ratio	-3.41	-228.69	-3.98	n/a	n/a
P/OCF Ratio	-3.42	-228.69	-4.01	n/a	n/a
OCF/S Ratio	n/a	n/a	n/a	n/a	n/a
Debt / Equity Ratio	0.01	n/a	-1.10	-1.97	-2.01
Quick Ratio	12.14	10.40	n/a	n/a	n/a
Current Ratio	12.14	10.40	n/a	n/a	n/a
Asset Turnover	n/a	n/a	n/a	n/a	n/a
Interest Coverage	n/a	n/a	n/a	n/a	n/a
Return on Equity	-32.61%	-39.36%	101.78K%	16.09%	236.19%
Return on Assets	-29.90%	-38.20%	-19.44K%	-2.43%	-30.05%
Return on Invested Capital	-35.23%	-41.63%	-992.51K%	-16.58%	-233.05%
Dividend Yield	n/a	n/a	n/a	n/a	n/a
Payout Ratio	n/a	n/a	n/a	n/a	n/a
FCF Payout Ratio	n/a	n/a	n/a	n/a	n/a
Gross Profit Margin	n/a	n/a	n/a	n/a	n/a
Net Profit Margin	n/a	n/a	n/a	n/a	n/a
Pretax Profit Margin	n/a	n/a	n/a	n/a	n/a
Operating Profit Margin	n/a	n/a	n/a	n/a	n/a
FCF Margin	n/a	n/a	n/a	n/a	n/a
EBITDA Margin	n/a	n/a	n/a	n/a	n/a